SCHEMBL3461492

SCHEMBL3461492

CNC(=O)c1nc(-c2cccc(C(=O)NCc3ccc(OCCN4CCOCC4)cc3)c2)cnc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.57
KDM1A O60341 1/20 0.57
ATR Q13535 6/20 0.51
KDR P35968 2/20 0.50
ROCK2 O75116 1/20 0.50
ROCK1 Q13464 1/20 0.50
MAP4K4 O95819 1/20 0.49
CCNE2 O96020 1/20 0.48
CCNE1 P24864 1/20 0.48
CDK2 P24941 1/20 0.48
GSK3B P49841 1/20 0.48
ACVR1 Q04771 1/20 0.46
SRC P12931 2/20 0.46
ABL1 P00519 1/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
LYN P07948 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
BCR P11274 1/20 0.46
TUBA1B P68363 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3459745 0.93 ROCK1 (0.59) HDAC1KDM1AATRKDRROCK2
SCHEMBL3460166 0.87 ATR (0.52) ATRMAP4K4PIK3CDPIK3CAPIK3CG
SCHEMBL3822499 0.87 PIK3CD (0.52) HDAC1ATRROCK2ROCK1CCNE2
SCHEMBL3460624 0.86 ATR (0.59) HDAC1KDM1AATRACVR1PIK3CD
SCHEMBL3460347 0.83 PIK3CD (0.55) HDAC1KDM1AATRPIK3CDPIK3CA
SCHEMBL3460819 0.82 ATR (0.64) HDAC1KDM1AATRPIK3CDPIK3CA
SCHEMBL3469202 0.82 ATR (0.49) ATRROCK2ROCK1PIK3CDPIK3CA
SCHEMBL3460577 0.82 KDM1A (0.54) HDAC1KDM1AATRPIK3CDPIK3CA
SCHEMBL3461030 0.81 PIK3CD (0.53) ATRPIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL3461795 0.81 PIK3CD (0.59) ATRPIK3CDPIK3CAPIK3CGPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 EP claimed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US claimed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 EP disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 US disclosed
EP-1501514-A4 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-08-26 EP disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 EP disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 HDAC1 923/4885KDM1A 2334/4885ATR 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.